Please use this identifier to cite or link to this item:
http://10.1.7.192:80/jspui/handle/123456789/12043
Title: | Adoption of Digital Health Initiatives in Chronic Disease Segment in Patient Engagement Domain by Pharmaceutical Companies: Triggers and Impact |
Authors: | Jathal, Keyur Kamlesh |
Keywords: | Ph.D Thesis Thesis - IM MT MT000082 |
Issue Date: | 9-Jun-2023 |
Series/Report no.: | MT000082; |
Abstract: | Chronic diseases are the largest contributors to the Global Burden of Disease. As per World Health Organization, 41 million people died of non-communicable diseases. In India, chronic diseases account for 60% of deaths nationally. Covid-19 pandemic-induced lock downs made remote patient engagement a necessity and digital health assumed unprecedented importance as managing chronic diseases was a global priority. Digital health initiatives (DHI) in the form of mobile health (mhealth) apps, virtual consultations, connected and wearable devices, gained prominence for remote patient engagement. The objective of this research was to seek an understanding on the adoption of DHI by pharmaceutical companies, in the patient engagement domain for managing chronic diseases. Research questions focused on the types of DHI adopted, along with the triggers for adoption and the impact. An integrated approach of the Technology-Organization- Environment (TOE) framework and the Iacovou model was treating a guiding reference to understand the adoption. A qualitative approach using the case study method was adopted, using both primary and secondary data collection methods. The research was structured in two phases. The first phase focused on addressing the research questions around the adoption of DHI by global pharma companies, which were headquartered in the US, UK, and Japan. The second phase focused on addressing the questions pertaining to the pharmaceutical companies operating in India. Thematic content analysis was adopted to analyze the qualitative data generated from interviews with senior leadership team members. There were 70 initiatives studied in phase 1, and 24 initiatives in phase 2. Interviews with 18 individuals were conducted. The findings indicated that there were three categories of DHI that were adopted, these were the diagnosis, treatment, and drug development phases. The major triggers for DHI adoption were Covid-19 pandemic, poor medication adherence, and the emerging technology landscape. The impact was realized both for the pharmaceutical company as well as the patient segment. The data collected, helped in addressing the research questions. The findings of the research were able to enrich the T-O-E and Iacovou model in the context of the DHI adoption by pharmaceutical companies and add to the body of knowledge. The findings also presented implications for the industry as well as policymakers in terms of the adoption of digital initiatives and regulations pertaining to patient data. |
Description: | 127p |
URI: | http://10.1.7.192:80/jspui/handle/123456789/12043 |
Appears in Collections: | Thesis, IM |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
MT000082.pdf | 10.52 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.